The fact that BemA has multiple mechanisms of action, including not only PPARα agonism, but also KHK inhibition and PNPLA3 induction, makes it an attractive candidate for NAFLD treatment. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.